Prospective study on cervical neoplasia: Presence of HPV DNA in cytological smears precedes the development of cervical neoplastic lesions

Sexually Transmitted Infections

Volumn 79, Issue 3, 2003, Pages 191-196

  Tachezy, Ruth ^a   Salakova M ^a   Hamsikova E ^a   Kanka J ^b   Havrankova A ^b   Vonka, V ^b  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY;

ADULT; ARTICLE; CANCER RISK; CLINICAL TRIAL; COHORT ANALYSIS; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; CZECHOSLOVAKIA; DNA DETERMINATION; DNA EXTRACTION; DNA FINGERPRINTING; FEMALE; FRANCE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROLOGY; SEXUAL INTERCOURSE; SMOKING HABIT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR DIAGNOSIS; UTERINE CERVIX TUMOR; VAGINA SMEAR; WART VIRUS;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; DNA, VIRAL; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 0037636393     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.79.3.191     Document Type: Article

References (38)

1. Vonka V, Kanka J, Jelinek J, et al. Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. I. Epidemiological characteristics. Int J Cancer 1984;33:49-60.
2. Vonka V, Kanka J, Hirsch I, et al. Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. II. Herpes simplex type-2 antibody presence in sera taken at enrollment. Int J Cancer 1984;33:61-6.
3. Krcmár M, Suchanková A, Kanka J, et al. Prospective study on the relationship between cervical neoplasia and herpes simplex type 2 virus. III. Presence of herpes simplex type-2 antibody in sera of subjects who developed cervical neoplasia later in the study. Int J Cancer 1986;38:161-5.
4. Durst M, Gissmann L, Ikenberg H, et al. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 1983;80:3812-15.
5. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
6. De Roda Husman AM, Walboomers JM, Meijer CJ, et al. Analysis of cytomorphologically abnormal cervical scrapes for the presence of 27 mucosotropic human papillomavirus genotypes, using polymerase chain reaction. Int J Cancer 1994;56:802-6.
7. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-71.
8. Liaw KL, Glass AG, Manos MM, et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst 1999;91:954-60.
9. Remmink AJ, Walboomers JM, Helmerhorst TJ, et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease:natural history up to 36 months. Int J Cancer 1995;61:306-11.
10. Dillner J. Antibody responses to defined HPV epitopes in cervical neoplasia. Papillomavirus Rep 1994;5:35-41.
11. Kirnbauer R, Hubbert NL, Wheeler CM, et al. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 1994;86:494-9.
12. Nonnenmacher B, Hubbert NL, Kirnbauer R, et al. Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain. J Infect Dis 1995;172:19-24.
13. Tachezy R, Hamsikova E, Hajek T, et al. Human papillomavirus genotype spectrum in Czech women:correlation of HPV DNA presence with antibodies against HPV-16, 18, and 33 virus-like particles. J Med Virol 1999;58:378-86.
14. Carter JJ, Koutsky LA, Wipf GC, et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996;174:927-36.
15. Dillner J, Lehtinen M, Bjorge T, et al. Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst 1997;89:1293-9.
16. Lehtinen M, Dillner J, Knekt P, et al. Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma:nested case-control study. BMJ 1996;312:537-9.
17. Vonka V, Hamsikova E, kanka J, et al. Prospective study on cervical neoplasia IV. Presence of HPV antibodies. Int J Cancer 1999;80:365-8.
18. De Gruijl TD, Bontkes HJ, Walboomers JM, et al. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. J Natl Cancer Inst 1997;89:630-8.
19. De Sanjose S, Hamsikova E, Munoz N, et al. Serological response to HPV16 in CIN-III and cervical cancer patients. Case-control studies in Spain and Colombia. Int J Cancer 1996;66:70-4.
20. Hamsikova E, Novak J, Hofmannova V, et al. Presence of antibodies to seven human papillomavirus type 16- derived peptides in cervical cancer patients and healthy controls. J Infect Dis 1994;170:1424-31.
21. Viladiu P, Bosch FX, Castellsague X, et al. Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer. J Clin Oncol 1997;15:610-19.
22. Stoppler H, Stoppler MC, Schlegel R. Transforming proteins of the papillomaviruses. Intervirology 1994;37:168-79.
23. Saiki RK, Scharf S, Faloona F, et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 1985;230:1350-4.
24. Snijders PJ, van den Brule AJ, Schrijnemakers HF, et al. The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. J Gen Virol 1990;71:173-81.
25. Kutinova L, Vonka V, Rezacova D. Plaque formation by NWS influenza virus in a human diploid cell strain. Acta Virol 1967;11:372-8.
26. Friedl F, Kimura I, Osato T, et al. Studies on a new human cell line (SiHa) derived from carcinoma of uterus. I. Its establishment and morphology. Proc Soc Exp Biol Med 1970;135:543-5.
27. Manos MM, Ting Y, Wright DK, et al. Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cell/ Molecular diagnostics of human cancer 1989;7:209-14.
28. Bauer HM, Ting Y, Greer CE, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991;265:472-7.
29. Tachezy R, Van Ranst MA, Cruz Y, et al. Analysis of short novel human papillomavirus sequences. Biochem Biophys Res Commun 1994;204:820-7.
30. Snijders PJ, Meijer CJ, Walboomers JM. Degenerate primers based on highly conserved regions of amino acid sequence in papillomaviruses can be used in a generalized polymerase chain reaction to detect productive human papillomavirus infection. J Gen Virol 1991;72:2781-6.
31. Kjaer SK, van den Brule AJ, Bock JE, et al. Human papillomavirus-the most significant risk determinant of cervical intraepithelial neoplasia. Int J Cancer 1996;65:601-6.
32. Melkert PW, Hopman E, van den Brule AJ, et al. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer 1993;53:919-23.
33. Lungu O, Sun XW, Wright TCJ, et al. A polymerase chain reaction-enzyme-linked immunosorbent assay method for detecting human papillomavirus in cervical carcinomas and high-grade cervical cancer precursors. Obstet Gynecol 1995;85:337-42.
34. Durst M, Kleinheinz A, Hotz M, et al. The physical state of human papillomavirus type 16 in benign and malignant genital tumors. J Gen Virol 1985;66:1515-22.
35. Schwarz E, Freese UK, Gissmann L, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 1985;314:111-14.
36. Wagatsuma M, Hashimoto K, Matsukura T. Analysis of integrated human papillomavirus type 16 DNA in cervical cancers:amplification of viral sequences together with cellular flanking sequences. J Virol 1990;64:813-21.
37. Van den Brule AJ, Walboomers JM, du Maine M, et al. Difference in prevalence of human papillomavirus genotypes in cytomorphologically normal cervical smears is associated with a history of cervical intraepithelial neoplasia. Int J Cancer 1991;48:404-8.
38. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000;181:1911-19.